Depressive symptoms are common in Parkinson’s disease and are thought to be caused by a loss of serotonin releasing cells which occurs in Parkinson’s disease. Before this study, there had not been well-designed clinical trials of antidepressant pharmacotherapy for depression in PD.
This multicenter study was designed to compare the efficacy and tolerability of two established medications (venlafaxine [Effexor XR] and paroxitene [Paxil]) versus placebo over a 12-week period. Information regarding the effects of these medications on motor function, quality of life and cognition will be analyzed. Participants of this study had a diagnosis of Parkinson’s disease and depressive symptoms.
The results of this study have not yet been reported. A publication in a medical journal is expected within the next year.